Patents by Inventor Shin Mineishi

Shin Mineishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR STEM CELL TRANSPLANTATION
    Publication number: 20220265720
    Abstract: The present disclosure provides methods of hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure provides a method of HSCT using a combination of an in-vivo T-cell depletion method, with an ex-vivo method of ?? T cell expansion and as T cell depletion. The in-vivo T-cell depletion method depletes (in-vivo) the alloreactive T cells that would otherwise increase the risk of GvHD.
    Type: Application
    Filed: March 10, 2022
    Publication date: August 25, 2022
    Inventors: Lawrence S. LAMB, Shin MINEISHI, Ayman SAAD
  • METHODS FOR STEM CELL TRANSPLANTATION
    Publication number: 20190183930
    Abstract: The present disclosure provides methods of hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure provides a method of HSCT using a combination of an in-vivo T-cell depletion method, with an ex-vivo method of ?? T cell expansion and ?? T cell depletion. The in-vivo T-cell depletion method depletes (in-vivo) the alloreactive T cells that would otherwise increase the risk of GvHD.
    Type: Application
    Filed: August 25, 2016
    Publication date: June 20, 2019
    Inventors: Lawrence S LAMB, Shin MINEISHI, Ayman SAAD
  • Double mutants of dihydrofolate reductase and methods of using same
    Patent number: 6887467
    Abstract: New mutant forms of human dihydrofolate reductase (DHFR) which have properties superior to the previously disclosed mutants have mutations at both amino acid 22 and amino acid 31. Specific mutant forms are Ser31Tyr22, Ser31Phe22, Gly31Tyr22, Gly31Phe22, Ala31Tyr22 and Ala31Phe22. The mutant DHFR of the invention may be used as a selectable marker, and to modify the genome of human cells, particularly bone marrow cells or peripheral blood stem cells, to render them resistant to chemotherapy using antifolate agents.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: May 3, 2005
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Joseph R. Bertino, Emine A. Ercikan-Abali, Debabrata Banerjee, Shin Mineishi, Michel Sadelain
  • Double mutants of dihydrofolate reductase and methods of using same
    Patent number: 6642043
    Abstract: New mutant forms of human dihydrofolate reductase (DHFR) which have properties superior to the previously disclosed mutants have mutations at both amino acid 22 and amino acid 31. Specific mutant forms are Ser31Tyr22, Ser31Phe22, Gly31Tyr22, Gly31Phe22, Ala31Tyr22 and Ala31Phe22. The mutant DHFR of the invention maybe used as a selectable marker, and to modify the genome of human cells, particularly bone marrow cells or peripheral blood stem cells, to render them resistant to chemotherapy using antifolate agents.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: November 4, 2003
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Joseph R. Bertino, Emine A. Ercikan-Abali, Debabrata Banerjee, Shin Mineishi, Michel Sadelain